Abstract
AbstractAchieving complete tumor resection is challenging and can be improved by real-time fluorescence-guided surgery with molecular-targeted probes. However, pre-clinical identification and validation of probes presents a lengthy process that is traditionally performed in animal models and further hampered by inter- and intra-tumoral heterogeneity in target expression. To screen multiple probes at patient scale, we developed a multispectral real-time 3D imaging platform that implements organoid technology to effectively model patient tumor heterogeneity and, importantly, healthy human tissue binding.
Funder
Stichting Villa Joep
EC | ERC | HORIZON EUROPE European Research Council
Princess Maxima Center for pediatric oncology
Oncode Institute
Publisher
Springer Science and Business Media LLC